Anrukinzumab
In this article, we are going to explore the fascinating world of Anrukinzumab. From its impact on today's society to its relevance in history, Anrukinzumab has captivated the attention of many people over the years. Through detailed analysis, we will examine the different facets of Anrukinzumab, unraveling its mysteries and discovering its true meaning. With a critical and objective perspective, we will immerse ourselves in the multiple dimensions of Anrukinzumab, seeking to understand its importance and influence in various spheres of life. So get ready for an exciting journey as we delve deeper into the topic of Anrukinzumab and discover everything it has to offer.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL13 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6452H9954N1714O2024S46 |
| Molar mass | 145393.34 g·mol−1 |
  (what is this?) (verify) | |
Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.
Anrukinzumab was developed by Wyeth.
References
- ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |